Nov 12, 2026: a 24% drop at the open, then half of it back

Twist closed Nov 11 at $122.59. Early premarket trades at 4am were as high as $129.44. Results came out at 7:15am, and Investing.com reported the stock down 7.1% before the open. By 9:25am it traded at $100.00. It opened at $99.59, set its low of $93.67 in the first minutes, and then climbed through the morning to $111.97 at 11:49am, down 8.7%, on about 2.9 million shares.

What pushed it down:

  • The AI drug discovery assumption. The fiscal 2027 guide assumes $100 million from AI drug discovery, up from $59.1 million in fiscal 2026, which had grown 175% from $21.5 million. Chief executive Emily Leproust said the figure reflects revenue the company can forecast with high confidence, with upside if capacity grows, and analysts asked why growth would slow when management had pointed to triple-digit order growth, Investing.com reported.
  • A guide near consensus. Revenue of $550 million to $560 million for fiscal 2027 is growth of about 21% at the midpoint, slower than the 28% of the fourth quarter, and close to the roughly $549 million analysts expected.
  • Valuation. Investing.com noted that the price-to-sales ratio was well above Twist's own history and its industry before the report. Our explainer on the price-to-sales ratio covers when a high multiple can hold.
  • Short sellers. Short interest was about 16% of the float, and insiders sold about $146.7 million of stock over the past twelve months, Investing.com reported. Our guide on how to evaluate a short seller report covers how to weigh that kind of pressure.

Bar chart of Twist Bioscience AI drug discovery revenue: $21.5 million in fiscal 2025, $59.1 million in fiscal 2026 and $100 million assumed in the fiscal 2027 guide

Peers moved far less. At 11:49am:

Stock or fundChange from Nov 11 close
Twist Bioscience (TWST)-8.7%
Illumina (ILMN)-0.6%
10x Genomics (TXG)-3.1%
Thermo Fisher Scientific (TMO)-1.6%
Danaher (DHR)0.0%
AbCellera Biologics (ABCL)-1.0%
Recursion Pharmaceuticals (RXRX)-4.2%
Invesco QQQ Trust (QQQ)+0.1%
iShares Russell 2000 ETF (IWM)-0.7%

After the drop, RSI(14) stood at 38, the shares sat 26% below their 50-day average and 21% above their 200-day average, volume ran 1.2 times its 20-day average, and the stock was 49% below its 52-week high of $219.71. More of today's biggest stock moves are on the market page.

The numbers

MeasureQ4 FY2025Q4 FY2026Change
Revenue$99.0M$126.6MUp 28%
DNA Synthesis and Protein Solutions$46.0M$61.0MUp 33%
NGS Applications$53.0M$65.7MUp 24%
Gross margin51.3%53.1%Up 1.8 points
Net loss$27.1M$20.6MNarrower
Loss per share$0.45$0.32Narrower
Adjusted EBITDA($7.8M)$2.2MPositive

For the full year, revenue rose 22% to $459.4 million, the company shipped about 1.3 million genes against about 938,000, and it served about 4,100 customers against 3,800. Selling, general and administrative costs rose to $301.2 million from $247.0 million, so the full-year net loss widened to $130.2 million from $77.7 million. Our explainer on how guidance changes move stocks covers why the outlook outweighed the quarter.

The bull case

Twist has grown revenue sequentially for 15 quarters in a row, and it guides the December quarter to $130 million to $132 million, 26% growth at the midpoint. Gross margin is above 52% and guided to 52.5% to 53% next year, and the company expects positive adjusted EBITDA for the full year. The capacity plan, about $75 million of capital spending in fiscal 2027 as part of $150 million over two years, is meant to support more than $1 billion of annual revenue in existing buildings. If AI-designed antibodies and proteins keep sending more work to outside labs, the $100 million assumption may prove low, and management framed it that way.

The risks

  • The multiple. At about 12 times next year's revenue net of cash, the stock leaves little room for any slowdown, and the fiscal 2027 guide already shows growth slowing to 21% from 22% for the year and 28% for the fourth quarter.
  • Concentration in one theme. Much of the 2026 rally rested on AI drug discovery, which was about 13% of revenue in fiscal 2026. A slower pace there changes the story more than the numbers.
  • Dilution. Twist raised about $425 million from share sales in fiscal 2026. Our explainer on dilution and share count changes covers what that does to per-share value.
  • Volatility. The stock fell 15.4% on Nov 5 and 23.6% at the low today. Our guide to post-earnings drift covers how stocks can keep moving after a report.

What comes next

  1. Fiscal first-quarter results, which we expect around February 2, 2027. Watch revenue against $130 million to $132 million and the AI drug discovery run rate against the $100 million full-year assumption.
  2. Analyst estimates. With the guide close to consensus, estimates may move little, so the direction of the stock depends more on the multiple than on revisions.
  3. Capacity. Progress on the new integrated systems and writers will show whether Twist can take on more AI-driven work than it guided.

Our guide on how to analyze an earnings call transcript covers how to read the analyst questions on a call like this one.